Browse

You are looking at 1 - 2 of 2 items for :

  • Diabetic kidney disease x
  • Refine by Content Type: All x
Clear All Modify Search

Join ASN for New Approaches to Transform Outcomes for Kidney Disease and Heart Disease in Patients with Diabetes, a videoconference scheduled for Thursday, December 10, from 4:00 – 5:30 PM EST. 

International clinical experts will review the latest guidelines for both kidney disease and cardiovascular disease, and discuss the most recent clinical trials and promising therapies, including the groundbreaking use of SGLT2 inhibitors to reduce morbidity and mortality.  These are among the first new therapies demonstrated to help prevent the development of heart disease and reduce progression of kidney disease in people with T2DM.

ASN Staff

The U.S. FDA has now approved INVOKANA® (canagliflozin) as the only type 2 diabetes (T2D) medicine indicated to treat diabetic kidney disease (DKD) and reduce the risk of hospitalization for heart failure in patients with T2D and DKD.  Approximately 1 in 3 patients with T2D also has DKD, which can ultimately lead to kidney failure. Once patients reach kidney failure, the average 5-year survival is less than 40%, largely due to cardiovascular-associated morbidity and mortality. This is the first new treatment option in nearly 20 years indicated to slow the progression of DKD in these patients.